Startup Tax Relief
for startups

UK startups have access to numerous HMRC tax reliefs that can significantly reduce tax burdens and improve cash flow during critical early years. From R&D tax credits under the merged scheme, which return 20% of qualifying development costs (27% for R&D-intensive SMEs) as a cash payment or corporation tax reduction, to SEIS/EIS schemes that make your business highly attractive to investors, understanding and claiming these reliefs is essential.

The complexity of startup tax reliefs means many entrepreneurs miss valuable opportunities. Business Asset Disposal Relief can save hundreds of thousands in capital gains tax on business sales, whilst loss relief allows trading losses to offset other income. Our specialist accountants stay current with all available reliefs and ensure your startup claims every benefit it's entitled to.

They understand how different reliefs interact, preventing situations where claiming one relief inadvertently reduces eligibility for others. Their expertise extends to advance planning, structuring your business activities to maximise future relief claims whilst maintaining commercial objectives.

The UK startup tax relief stack is one of the most generous in any developed economy, but it's also one of the most fragmented. Five major regimes interact: the merged R&D tax credit scheme (replaced the old SME enhanced deduction in April 2024), SEIS and EIS for equity investment, the Annual Investment Allowance for capital expenditure, EMI for employee share options, and Business Asset Disposal Relief for founder exits. Each carries its own eligibility tests, qualifying periods, claim mechanics, and HMRC enforcement intensity. Stacked correctly, they can return 30-50% of total development spend to the business in cash or corporation tax savings during the first three years. Stacked incorrectly, they conflict with each other (notified state aid grants disqualify R&D claim costs, SEIS shares can't be issued to existing employees post-grant of EMI options that have vested, etc.), and the compounded loss can exceed any one relief's value.

R&D tax credits are the largest single relief for most pre-revenue tech startups. Under the merged scheme effective for accounting periods beginning on or after 1 April 2024, all UK companies claim a 20% above-the-line credit on qualifying R&D expenditure, with R&D-intensive SMEs (where R&D is over 30% of total spending) claiming an enhanced 27% rate. Loss-making companies can elect to surrender the credit for a cash payment from HMRC, typically arriving 4-6 weeks after a clean claim is submitted. Qualifying expenditure includes staff salaries (the relevant proportion attributed to R&D activity), externally provided workers (with the post-2024 restrictions on overseas costs), software directly used in R&D, and consumables. The new mandatory Additional Information Form, the pre-notification requirement for first-time claimants, and HMRC's increased enquiry rate (now around 1 in 5 SME claims) have all materially raised the bar for claim quality. Casual or DIY R&D claims are now genuinely risky.

SEIS and EIS are the equity-side of the startup relief stack. SEIS provides 50% income tax relief to investors on subscriptions up to £200,000 per tax year per investor, plus capital gains tax exemption on the eventual sale of SEIS shares (held for three or more years). The company can raise up to £250,000 of SEIS investment in its lifetime. EIS provides 30% income tax relief on subscriptions up to £1m per tax year (or £2m where the additional amount is invested in knowledge-intensive companies) and similar CGT exemption. Both schemes require a specific share class (ordinary, full risk-bearing), specific issuance procedures (shares fully paid up in cash at issuance), and three-year qualifying conditions on both the company's activities and the investor's holding. Advance assurance from HMRC, while not strictly required, is universally expected by investors and substantially de-risks the round. Most UK startups raising any institutional or angel money structure their first round as SEIS, then transition to EIS once the SEIS limit is reached.

The Annual Investment Allowance gives 100% first-year corporation tax deduction on qualifying plant and machinery up to £1 million per year. For most startups this is more than they'll spend on capital equipment in any single year. Full Expensing (introduced April 2023, made permanent in April 2024) extends the 100% first-year deduction to most main-rate plant and machinery with no upper cap, available to companies (not unincorporated businesses). Software and IT equipment qualify for AIA; vehicles and structures and buildings have separate regimes. The accountant's job here is timing - accelerating planned capex into the right accounting period to land the deduction in a year when the company has corporation tax to set against, not in a loss-making year where the deduction would just enlarge the loss.

EMI option schemes are the standard UK mechanism for granting equity to employees in a tax-efficient way. EMI requires HMRC qualification (a written scheme document, valuations agreed with HMRC where possible, and ongoing reporting), and qualifying companies have to meet limits on gross assets (£30m), employee count (250 full-time equivalent), and qualifying trade (excludes financial services, property development, legal). Granted options have to be exercised within 10 years and within the £250,000 per-employee unexercised option limit. When exercised at or above the agreed grant-date market value, the gain is taxed as a capital gain on disposal of the resulting shares (potentially at 10% under BADR if the holding period is met) rather than as employment income (at up to 47% combined rate). For an early-stage startup granting £100k of options to a senior hire, the EMI structure can save the employee £37k+ in tax versus an unapproved option, which makes the cost of running the scheme negligible by comparison.

Business Asset Disposal Relief sits at the end of the stack, applied at the point of founder exit. BADR reduces capital gains tax to 10% on up to £1 million of lifetime gains from selling shares in a personal trading company, provided the founder held at least 5% of the ordinary share capital and voting rights for at least two years before the disposal, and was an employee or director throughout the qualifying period. The 5% test was clarified in 2018 to require both economic and voting rights and tightened in 2020 to require alignment of all five statutory conditions for the full two-year period. Many founders discover at deal-room that some structural change made years earlier (a share class restructure, a spouse's holding falling below 5%, an inadvertent gap in director status during a parental leave) has broken the BADR clock, costing them an effective 14% of the gain. Pre-exit planning to ensure all conditions are met is materially cheaper than discovering the problem at SPA stage.

R&D claim defence after a HMRC enquiry letter is a different engagement from a standard R&D claim. Once HMRC opens a check (typically four to twelve weeks after submission, sometimes years later for more complex cases), the company faces a structured set of questions about technical narrative, cost methodology, and contemporaneous records. The accountant has to produce evidence the company already had at the time the work was done - retrospectively reconstructing a justification almost always weakens the position. The standard 28-day cash payment timeline is paused during the enquiry, often for six months or more, which can be cash-flow fatal for a pre-revenue startup. Specialist R&D advisors who handle enquiries regularly know what HMRC is looking for and can usually settle within the original claim envelope, but DIY claims and claims prepared by generalists are now closing at 60-70% of the originally submitted amount.

Notified state aid grants (Innovate UK, Horizon Europe successor schemes, and certain Welsh Government and Scottish Enterprise grants) interact with R&D claims in ways that catch many companies. Where a project receives notified state aid, the costs covered by the grant cannot also be claimed under the SME R&D relief - the company has to choose. Under the merged scheme this complication has reduced (the merged scheme is treated as not being notified state aid for most purposes), but the timing of grant receipts and R&D periods still matters. A company that takes a £200k Innovate UK grant for a specific project should expect the R&D claim on that project's costs to be reduced or denied; planning the project boundaries and grant scope at the start lets the accountant maximise the eligible R&D expenditure outside the grant scope.

SEIS and EIS qualifying conditions have to hold continuously for three years after the share issue, not just at the point of issue. A company that issues SEIS shares and then drifts into a non-qualifying activity (for example, expanding into a property-investment side business, or pivoting to a financial services product), or that breaches the gross assets test through a successful round, can have the relief clawed back from investors. The three-year clock applies separately to each share issue, meaning a company that raises three SEIS rounds carries three overlapping three-year qualifying periods. Investor-protection clauses in SEIS-friendly Shareholders' Agreements typically require the company to maintain qualifying status for the full period and to indemnify investors against clawback caused by company action - which gives investors a contractual cause of action against founders who steer the company into non-qualifying activities.

Loss relief interactions with the rest of the relief stack are the area most generalists get wrong. A loss-making startup with significant R&D expenditure has multiple options: surrender the R&D credit for cash, carry the trading loss forward to set against future profits, carry the loss back to set against prior-year profits (limited circumstances), or - in a group structure - surrender the loss to a profitable group company via group relief. Each choice has different cash, timing, and tax-rate implications. The R&D cash credit pays at the lower rate (10p in the pound under the merged scheme, vs the marginal rate of 19-26.5% on a future-profit deduction), so for a company expecting profit recovery the carry-forward is usually higher value. For a company with no certain profit horizon, the cash credit is more reliable. The right answer turns on the company's specific cash position, profit forecast, and tax rate - and is the kind of decision an annual accountant can recalibrate as the trading position evolves.